Skip to main content

BioNTech vs Pfizer: Strategic Comparison

Direct Answer

Pfizer is far bigger: it reported $62.579 billion of revenue and $7.771 billion of net income for fiscal 2025, versus BioNTech's €2.870 billion of revenue (about $3.2 billion) and a ~$1.28 billion (€1.136 billion) net loss for the same year. Pfizer employed about 75,000 people at the end of 2025, compared with BioNTech's 7,807. The two are not head-to-head rivals on COVID-19 vaccines, since they jointly developed Comirnaty and still split its profit; where they do compete is oncology, where both are chasing new cancer drugs.

Pfizer and BioNTech are not rivals in the usual sense: they are 50:50 partners on Comirnaty, the COVID-19 vaccine that made both companies famous, yet Pfizer's FY2025 revenue of $62.579 billion was roughly 19 times BioNTech's €2.870 billion (about $3.2 billion at 2025's average €1.13-per-dollar rate), largely because Pfizer books the vaccine's full sale price while BioNTech records only its half of the gross profit. Pfizer was founded in 1849 in Brooklyn by Charles Pfizer and Charles Erhart; BioNTech was founded in 2008 in Mainz, Germany, by oncologists Ugur Sahin, Özlem Türeci and Christoph Huber. Albert Bourla has been Pfizer's Chairman and CEO since January 1, 2019, while Sahin has run BioNTech since its founding and is due to hand the role to former Sobi chief executive Guido Oelkers by February 1, 2027. For fiscal 2025, Pfizer posted $7.771 billion of net income on about 75,000 employees, while BioNTech posted a ~$1.28 billion (€1.136 billion) net loss on about 7,807 employees, despite still holding ~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldBioNTech SEPfizer Inc.
Latest annual revenue~$3.2B (FY2025)$62.6B (FY2025)
Founded20081849
Employees7,80775,000
Market Cap$24.7B$160.3B
HeadquartersGermanyUnited States
Revenue / Employee$415k / employee$834k / employee
Valuation Multiple7.6x P/S2.6x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

BioNTech SE Strategic Vector

FY2025 Revenue Baseline

BioNTech's corporate strategy centers on deploying its multi-billion-dollar pandemic cash reserves to build a diversified, late-stage commercial oncology portfolio by 2026. Management is advancing clinical trials across multiple therapeutic modalities, including individualized neoantigen mRNA cancer vaccines, antibody-drug conjugates (ADCs) targeting solid tumors, and bispecific checkpoint immunotherapies. Under CEO Ugur Sahin, BioNTech is executing strategic partnerships and targeted biotechnology acquisitions to establish recurring commercial oncology revenues as pandemic vaccine demand normalizes.

Productivity: $415k / employee

Pfizer Inc. Strategic Vector

FY2025 Revenue Baseline

Following the historic pandemic revenue windfall, Pfizer's corporate strategy centers on redeploying capital into high-growth oncology franchises and structural cost alignment. Under Chief Executive Officer Albert Bourla, Pfizer executed the landmark forty-three-billion-dollar acquisition of Seagen Inc., instantly establishing Pfizer as a global powerhouse in targeted cancer therapies. Seagen added four commercialized antibody-drug conjugates (including Padcev, Adcetris, and Tukysa) and doubled Pfizer's oncology pipeline with specialized tumor-homing molecules. Concurrently, Pfizer launched a multi-billion-dollar enterprise cost realignment program to adjust operating expenses to post-pandemic baseline demand, while launching novel vaccines including Abrysvo for respiratory syncytial virus (RSV) protection in infants and older adults.

Productivity: $834k / employee
Comparative Divergence: The companies' partnership began in March 2020, when BioNTech licensed its mRNA science to Pfizer's global trial, manufacturing and regulatory machine, producing Comirnaty, the first authorized mRNA medicine, in December 2020. That alliance is now winding down on the commercial side: BioNTech said on September 28, 2026 that it would close its Tübingen, Marburg and Idar-Oberstein sites in Germany and a Singapore plant, handing all remaining Comirnaty manufacturing to Pfizer and affecting up to 1,860 jobs. Both companies have also become co-defendants rather than competitors in intellectual-property fights: Bayer's Monsanto unit sued Pfizer, BioNTech and Moderna in January 2026 over mRNA delivery technology, and BioNTech separately settled a related claim with CureVac and GSK for an aggregate $740 million in August 2025 before acquiring CureVac outright in December 2025. Where the two do compete is oncology, where BioNTech's Bristol Myers Squibb-partnered pumitamig and antibody-drug conjugates are entering the same crowded PD-(L)1 and ADC races that Pfizer's Seagen portfolio also targets.

BioNTech vs Pfizer Market Share

BioNTech SE market share
BioNTech does not report market share. Comirnaty has been the most widely sold mRNA COVID-19 vaccine; Arbutus and Genevant, which are suing Pfizer and BioNTech, put Comirnaty at about two-thirds of global COVID-19 mRNA vaccine sales to date in March 2026. In oncology BioNTech has no marketed products yet.
Pfizer Inc. market share
Pfizer ranks among the top pharmaceutical companies worldwide by revenue. Its strongest positions are in pneumococcal vaccines (Prevnar), anticoagulation (Eliquis, with BMS), ATTR cardiomyopathy (Vyndaqel family) and ADC-based bladder cancer treatment (Padcev).

Quick Stats Comparison

MetricBioNTech SEPfizer Inc.
Revenue~$3.2B (FY2025)$62.6B (FY2025)
Founded20081849
HeadquartersMainz, Rhineland-Palatinate, GermanyNew York, New York
Market Cap$24.7B$160.3B
Employees7,80775,000
Revenue / Employee$415k / employee$834k / employee
Valuation Multiple7.6x P/S2.6x P/S

BioNTech Revenue vs Pfizer Revenue — Year by Year

YearBioNTech SEPfizer Inc.Higher reported revenue
2025~$3.2B$62.6BPfizer Inc. (approx. USD)
2024~$3.1B$63.6BPfizer Inc. (approx. USD)
2023~$4.3B$59.6BPfizer Inc. (approx. USD)
2022~$19.6B$101.2BPfizer Inc. (approx. USD)
2021~$21.4B$81.3BPfizer Inc. (approx. USD)

Business Model Breakdown

Overview: BioNTech SE vs Pfizer Inc.

This in-depth comparison examines BioNTech SE and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching BioNTech SE on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between BioNTech SE and Pfizer Inc. is widest.

On the headline numbers, annual revenue is ~$3.2B (FY2025) for BioNTech SE and $62.6B (FY2025) for Pfizer Inc., while their respective market capitalizations stand at $24.7B and $160.3B. BioNTech SE is headquartered in Germany and Pfizer Inc. in United States, and those different home markets shape how each company competes.

BioNTech SE: BioNTech SE is a German biotechnology company headquartered in Mainz and listed on Nasdaq as BNTX. Physicians Ugur Sahin and Özlem Türeci founded it in 2008 with oncologist Christoph Huber to build individualized cancer immunotherapies on mRNA. That platform became Comirnaty, the Pfizer-BioNTech COVID-19 vaccine first authorized in December 2020, which earned BioNTech ~$11.6 billion (€10.29 billion) of net profit in 2021. Since 2023 the company has redirected the windfall into oncology: it bought Biotheus for full rights to pumitamig, licensed antibody-drug conjugates, partnered pumitamig with Bristol Myers Squibb, and acquired mRNA rival CureVac in December 2025. It had 7,807 employees at the end of 2025. The company is headquartered in Mainz, Germany.

Pfizer Inc.: Pfizer Inc. (NYSE: PFE) is one of the largest pharmaceutical companies in the world by revenue, headquartered at The Spiral, 66 Hudson Boulevard East, New York. It employs about 75,000 people and sells medicines in more than 180 countries. Its history includes Terramycin, Lipitor (via Warner-Lambert), Viagra, Prevnar (via Wyeth) and the Comirnaty COVID-19 vaccine developed with BioNTech. The company is headquartered in New York City, New York. Pfizer was founded in 1849 in Brooklyn, New York City, by German immigrant cousins Charles Pfizer and Charles F. Erhart as a fine-chemicals business, expanding over 175 years into a global biopharmaceutical giant discovering penicillin, Lipitor, Viagra, and the landmark COVID-19 vaccine Comirnaty.

Business Models: How BioNTech SE and Pfizer Inc. Make Money

BioNTech SE and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between BioNTech SE and Pfizer Inc..

BioNTech SE business model: BioNTech SE operates a biotechnology commercialization and clinical development model, generating revenue through commercial vaccine sales, pharmaceutical partnership profit splits, licensing agreements, and research milestone payments. The company commercializes the BNT162b2 (Comirnaty) mRNA COVID-19 vaccine globally in collaboration with Pfizer, sharing gross profits and manufacturing responsibilities. BioNTech also earns upfront licensing fees and milestone royalties from collaborative development programs with Bristol Myers Squibb, Genmab, and DualityBio, while reinvesting substantial capital into its wholly owned oncology pipeline.

Pfizer Inc. business model: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology. Historically recognized for blockbuster small molecules (Lipitor, Viagra, Eliquis) and pediatric vaccines (Prevnar family), Pfizer achieved unprecedented revenue scale by co-developing Comirnaty—the world's first authorized mRNA COVID-19 vaccine—with BioNTech, alongside the oral antiviral Paxlovid. The company monetizes intellectual property through global pharmaceutical distribution networks, selling to national governments, hospital purchasing organizations, and retail pharmacy chains across more than one hundred twenty countries.

Competitive Advantage: BioNTech SE vs Pfizer Inc.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of BioNTech SE stack up against those of Pfizer Inc..

BioNTech SE competitive advantage: BioNTech's economic moat is grounded in its proprietary mRNA technology platform, structural immunology expertise, and specialized clinical manufacturing infrastructure. Founded by translational oncology scientists Ugur Sahin and Özlem Türeci, BioNTech developed advanced mRNA sequence optimization algorithms, specialized lipid nanoparticle delivery formulations, and automated GMP manufacturing facilities that produce customized personalized neoantigen therapies. Its proven track record of bringing the world's first approved mRNA vaccine from design to commercial authorization in under a year provides immense scientific credibility and regulatory validation.

Pfizer Inc. competitive advantage: Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities. Few pharmaceutical corporations in the world possess the logistical capacity to conduct concurrent Phase 3 clinical trials involving tens of thousands of patients across dozens of countries while managing ultra-low-temperature cold-chain distribution. Pfizer's Prevnar pneumococcal conjugate vaccine family has maintained multi-decade commercial dominance due to the extreme complexity of polysaccharide-protein conjugation manufacturing. Pfizer's alliance with Bristol-Myers Squibb on the anticoagulant Eliquis provides reliable, high-margin cash flow, while its commercial relationships with national healthcare authorities enable rapid global drug rollouts.

Growth Strategy: Where BioNTech SE and Pfizer Inc. Are Headed

Future prospects matter as much as current results. The growth strategies below explain how BioNTech SE and Pfizer Inc. each plan to expand from here.

BioNTech SE growth strategy: BioNTech's stated goal is to become a multi-product oncology company by 2030. The plan rests on three groups of medicines: next-generation immunomodulators led by pumitamig, now in seven pivotal trials across lung, breast, colorectal and gastric cancer, and gotistobart; antibody-drug conjugates such as trastuzumab pamirtecan (HER2) and elfetabart drozuntecan (B7-H3), which has been given to more than 1,000 patients; and mRNA cancer immunotherapies including autogene cevumeran with Genentech. It is testing these assets together in more than ten novel-novel combinations, cutting non-focus programs, and handing all COVID-19 vaccine manufacturing to Pfizer to free cash for the clinic. Next-generation mRNA platform work is to be contributed to the founders' new company.

Pfizer Inc. growth strategy: Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total). Obesity: Pfizer acquired Metsera in November 2025 for about $10 billion including contingent value rights, after a bidding contest with Novo Nordisk. Cost: a multi-year cost realignment and manufacturing optimization program funds R&D and protects margins.

Financial Picture: BioNTech SE vs Pfizer Inc.

A closer look at the financial trajectory of BioNTech SE and Pfizer Inc. rounds out the comparison.

BioNTech SE: BioNTech went from a ~$202 million (€179.1 million) net loss in 2019 to ~$11.6 billion (€10.29 billion) of net profit on ~$21.4 billion (€18.98 billion) of revenue in 2021, almost all from Comirnaty. Revenue then fell to ~$19.6 billion (€17.31 billion) in 2022, ~$4.32 billion (€3.82 billion) in 2023 and ~$3.11 billion (€2.75 billion) in 2024, when it posted a ~$752 million (€665.3 million) net loss. FY2025 revenue rose 4.3% to ~$3.24 billion (€2.87 billion) only because BMS collaboration revenue was booked in Q3, while the net loss widened to ~$1.29 billion (€1.14 billion) on ~$2.37 billion (€2.10 billion) of R&D and legal settlement costs. In 2026 the decline resumed: H1 revenue fell to ~$253 million (€223.7 million), the H1 net loss reached ~$1.53 billion (€1.35 billion), and full-year revenue guidance was cut to €1.6-1.9 billion. The cushion is ~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026, which also funds a $1.0 billion ADS buyback launched in May 2026. BioNTech skyrocketed in value during the global pandemic, maintaining a market valuation generally exceeding $20 billion driven by its mRNA pipeline.

Pfizer Inc.: Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.

Company-Specific SWOT Notes

BioNTech SE

Strength

~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026, BMS cost-sharing on pumitamig, and 14 ongoing pivotal trials across bispecifics, ADCs and mRNA immunotherapies.

Strength

BioNTech pioneered clinically validated mRNA therapeutics in partnership with Pfizer (Comirnaty), building robust immunology and clinical expertise.

Weakness

Revenue guidance for 2026 was cut to €1.6-1.9 billion and H1 2026 net loss reached ~$1.53 billion (€1.35 billion), while every oncology product is still investigational.

Weakness

COVID-19 vaccine sales normalized substantially from pandemic peaks, leading to lower near-term commercial operating revenues.

Opportunity

Positive Phase 3 results for pumitamig, gotistobart or trastuzumab pamirtecan could give BioNTech its first cancer launches and move it toward its 2030 multi-product goal.

Threat

Summit, Akeso, Merck and others are racing in the same drug classes; Moderna, Bayer and Arbutus patent cases remain open; and the founders leave by the end of 2026.

Pfizer Inc.

Strength

Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.

Weakness

Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.

Weakness

The impending loss of exclusivity for blockbuster drugs like Eliquis and Ibrance threatens a significant portion of Pfizer's high-margin recurring revenue by 2027.

Opportunity

The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.

Threat

Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScalePfizer Inc.~$3.2B (FY2025) versus $62.6B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierPfizer Inc.BioNTech SE was founded in 2008; Pfizer Inc. was founded in 1849.
Verdict

Comparison Takeaway: BioNTech vs Pfizer

Pfizer is a diversified, profitable pharmaceutical giant with a 12.4% FY2025 net margin, leaning on the Seagen and Metsera acquisitions and new licensing deals with Innovent and 3SBio to replace revenue as Eliquis, Ibrance and other blockbusters face patent expiration later this decade. BioNTech is a single-platform biotech burning cash on an unproven oncology pipeline: it had no approved cancer product as of October 2026 and cut its 2026 revenue guidance to €1.6-1.9 billion in August 2026 as COVID-19 demand kept shrinking, even though its lead bispecific pumitamig is backed by a $1.5 billion upfront payment and up to $7.6 billion of milestones from Bristol Myers Squibb. The vaccine they share shows Pfizer's scale advantage directly: Pfizer runs manufacturing and distribution and keeps the full sale price on its books, while BioNTech records only its 50% gross-profit share, which is why BioNTech's revenue swings far harder than Pfizer's when COVID-19 demand shifts. BioNTech's ~$18.8 billion (€16.6 billion) cash pile at June 30, 2026 buys time to keep funding 14 pivotal oncology trials, but it is racing against both a shrinking vaccine business and a looming CEO transition to Guido Oelkers by February 1, 2027.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: BioNTech vs Pfizer

Is Pfizer bigger than BioNTech?

Yes, by a wide margin. Pfizer reported $62.579 billion of revenue for fiscal 2025, compared with BioNTech's €2.870 billion (about $3.2 billion), making Pfizer roughly 19 times larger by revenue. Pfizer also employed about 75,000 people at the end of 2025, versus BioNTech's 7,807.

Which is more profitable, Pfizer or BioNTech?

Pfizer. It earned $7.771 billion of net income in fiscal 2025, a 12.4% net margin, while BioNTech posted a ~$1.28 billion (€1.136 billion) net loss for the same year as COVID-19 vaccine demand kept falling and oncology R&D spending rose.

Who is the CEO of Pfizer and who runs BioNTech?

Albert Bourla has been Pfizer's Chairman and CEO since January 1, 2019. Ugur Sahin, who co-founded BioNTech in 2008, remains its CEO but is due to hand the role to former Sobi chief executive Guido Oelkers by February 1, 2027.

Do Pfizer and BioNTech split profit on the COVID-19 vaccine Comirnaty?

Yes. Outside Germany, Pfizer and BioNTech split Comirnaty's gross profit 50:50, with Pfizer handling sales and booking the full revenue while BioNTech records only its half of the profit. In Germany, BioNTech books its own direct Comirnaty sales as revenue instead.

Is Pfizer or BioNTech the better stock to own?

Pfizer is the larger, profitable, dividend-paying company, with a market capitalization of about $160.3 billion in late September 2026 against BioNTech's $24.69 billion. BioNTech is a higher-risk bet on its unproven oncology pipeline, cushioned by ~$18.8 billion (€16.6 billion) of cash as of June 30, 2026, but Pfizer offers steadier earnings today.

Which company was founded first, BioNTech SE or Pfizer Inc.?

Pfizer Inc. was founded in 1849; BioNTech SE was founded in 2008.

What revenue did BioNTech SE and Pfizer Inc. report?

BioNTech SE had ~$3.2B (FY2025), while Pfizer Inc. had $62.6B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do BioNTech SE and Pfizer Inc. make money?

BioNTech SE: BioNTech SE operates a biotechnology commercialization and clinical development model, generating revenue through commercial vaccine sales, pharmaceutical partnership profit splits, licensing agreements, and research milestone payments. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.

Which is better, BioNTech SE or Pfizer Inc.?

There is no evidence-based single winner. Compare BioNTech SE and Pfizer Inc. on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Pfizer is far bigger: it reported $62.579 billion of revenue and $7.771 billion of net income for fiscal 2025, versus BioNTech's €2.870 billion of revenue (about $3.2 billion) and a ~$1.28 billion (€1.136 billion) net loss for the same year. Pfizer employed about 75,000 people at the end of 2025, compared with BioNTech's 7,807. The two are not head-to-head rivals on COVID-19 vaccines, since they jointly developed Comirnaty and still split its profit; where they do compete is oncology, where both are chasing new cancer drugs.

Verdict

Pfizer is a diversified, profitable pharmaceutical giant with a 12.4% FY2025 net margin, leaning on the Seagen and Metsera acquisitions and new licensing deals with Innovent and 3SBio to replace revenue as Eliquis, Ibrance and other blockbusters face patent expiration later this decade. BioNTech is a single-platform biotech burning cash on an unproven oncology pipeline: it had no approved cancer product as of October 2026 and cut its 2026 revenue guidance to €1.6-1.9 billion in August 2026 as COVID-19 demand kept shrinking, even though its lead bispecific pumitamig is backed by a $1.5 billion upfront payment and up to $7.6 billion of milestones from Bristol Myers Squibb. The vaccine they share shows Pfizer's scale advantage directly: Pfizer runs manufacturing and distribution and keeps the full sale price on its books, while BioNTech records only its 50% gross-profit share, which is why BioNTech's revenue swings far harder than Pfizer's when COVID-19 demand shifts. BioNTech's ~$18.8 billion (€16.6 billion) cash pile at June 30, 2026 buys time to keep funding 14 pivotal oncology trials, but it is racing against both a shrinking vaccine business and a looming CEO transition to Guido Oelkers by February 1, 2027.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). BioNTech SE vs Pfizer Inc. Comparison. from https://corpdigest.com/compare/biontech-vs-pfizer

MLA Format

CorpDigest. "BioNTech SE vs Pfizer Inc. Comparison." CorpDigest, 2026, https://corpdigest.com/compare/biontech-vs-pfizer.

Chicago Format

CorpDigest. "BioNTech SE vs Pfizer Inc. Comparison." CorpDigest. 2026. https://corpdigest.com/compare/biontech-vs-pfizer.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.